For example, DDX10 and BYSL are presumed to be potential targets for chondrosarcoma,[20] in addition to IDH1/2 and COL2A1 as possible therapeutic targets for chondrosarcoma.[21] However, these studies are based on the molecular level and not on clinical features. This evidence concerns the gene BYSL and chondrosarcoma.